{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:09:22Z","timestamp":1768702162703,"version":"3.49.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bioorg.2025.109417","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:16:41Z","timestamp":1766819801000},"page":"109417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent process in the development of TIM-3 antibodies and small-molecule inhibitors for cancer immunotherapy"],"prefix":"10.1016","volume":"169","author":[{"given":"Fei","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Miu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubiao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanle","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bioorg.2025.109417_bb0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cac2.12178","article-title":"Advancing to the era of cancer immunotherapy","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun."},{"issue":"13","key":"10.1016\/j.bioorg.2025.109417_bb0010","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of Cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioorg.2025.109417_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.681320","article-title":"Clinical insights into novel immune checkpoint inhibitors","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109417_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109417_bb0025","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.3748\/wjg.v22.i7.2294","article-title":"Role of Tim-3 in hepatitis B virus infection: an overview","volume":"22","author":"Liu","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109417_bb0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/jmbi.1996.0726","article-title":"A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding11. Edited by I. A. Wilson","volume":"265","author":"Proba","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109417_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030676","article-title":"TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression","volume":"7","author":"Gao","year":"2012","journal-title":"PloS One"},{"issue":"5853","key":"10.1016\/j.bioorg.2025.109417_bb0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science (New York, N.Y.)"},{"issue":"16","key":"10.1016\/j.bioorg.2025.109417_bb0045","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bioorg.2025.109417_bb0050","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1084\/jem.20150388","article-title":"Tim-3 enhances Fc\u03b5RI-proximal signaling to modulate mast cell activation","volume":"212","author":"Phong","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2025.109417_bb0055","first-page":"1","article-title":"TIM-3 and its regulatory role in immune responses","volume":"350","author":"Zhu","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109417_bb0060","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2025.109417_bb0065","first-page":"10","article-title":"The role of TIM-3 in hepatocellular carcinoma: a promising target for immunotherapy?","author":"Ganjalikhani Hakemi","year":"2020","journal-title":"Front. Oncol."},{"issue":"7534","key":"10.1016\/j.bioorg.2025.109417_bb0070","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109417_bb0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/imm.13488","article-title":"TIM3\/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome","volume":"168","author":"Yu","year":"2023","journal-title":"Immunology"},{"issue":"17","key":"10.1016\/j.bioorg.2025.109417_bb0080","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1042\/BCJ20210425","article-title":"Phosphatidylserine binding directly regulates TIM-3 function","volume":"478","author":"Smith","year":"2021","journal-title":"Biochem. J."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109417_bb0085","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","article-title":"Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation","volume":"113","author":"Nakayama","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bioorg.2025.109417_bb0090","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid\u2013mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109417_bb0095","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.109417_bb0100","series-title":"Negative Co-Receptors and Ligands","first-page":"1","article-title":"TIM-3 and its regulatory role in immune responses","author":"Zhu","year":"2011"},{"issue":"8","key":"10.1016\/j.bioorg.2025.109417_bb0105","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bioorg.2025.109417_bb0110","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1158\/1078-0432.CCR-21-0261","article-title":"Safety and antitumor activity of \u03b1-PD-L1 antibody as monotherapy or in combination with \u03b1-TIM-3 antibody in patients with microsatellite instability-high\/mismatch repair-deficient tumors","volume":"27","author":"Hollebecque","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109417_bb0115","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-20-3716","article-title":"Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.bioorg.2025.109417_bb0120","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109417_bb0125","series-title":"A Phase Ib\/II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109417_bb0130","doi-asserted-by":"crossref","first-page":"v491","DOI":"10.1093\/annonc\/mdz253.028","article-title":"1202P - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti\u2013PD-1\/L1 therapy","volume":"30","author":"Mach","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.109417_bb0135","series-title":"ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-Emptive Therapy in AML): A Multi-arm, Precision-Based, Recursive, Platform Trial","year":"2024"},{"key":"10.1016\/j.bioorg.2025.109417_bb0140","series-title":"A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas","year":"2018"},{"key":"10.1016\/j.bioorg.2025.109417_bb0145","author":"Exploratory","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109417_bb0150","series-title":"A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)","year":"2016"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109417_bb0155","doi-asserted-by":"crossref","first-page":"oyaf144","DOI":"10.1093\/oncolo\/oyaf144","article-title":"First-in-human phase I open-label study of the anti\u2013TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors","volume":"30","author":"Gutierrez","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2025.109417_bb0160","series-title":"A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria","year":"2021"},{"key":"10.1016\/j.bioorg.2025.109417_bb0165","series-title":"A Phase I\/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0170","series-title":"Phase 1\u20132 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors","year":"2018"},{"key":"10.1016\/j.bioorg.2025.109417_bb0175","series-title":"An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0180","series-title":"A Phase 1\u20132 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109417_bb0185","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0190","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109417_bb0195","series-title":"A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","year":"2019"},{"key":"10.1016\/j.bioorg.2025.109417_bb0200","series-title":"Phase 1b, Multi-arm, Open-label Study of PDR001 and\/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","year":"2017"},{"key":"10.1016\/j.bioorg.2025.109417_bb0205","series-title":"A Phase I Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM","year":"2019"},{"key":"10.1016\/j.bioorg.2025.109417_bb0210","series-title":"A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome","year":"2021"},{"key":"10.1016\/j.bioorg.2025.109417_bb0215","series-title":"A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination with Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy","year":"2019"},{"key":"10.1016\/j.bioorg.2025.109417_bb0220","year":"2021"},{"key":"10.1016\/j.bioorg.2025.109417_bb0225","series-title":"A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria","year":"2019"},{"key":"10.1016\/j.bioorg.2025.109417_bb0230","series-title":"An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1\/TIM-3 Bispecific Antibody, in Patients With Advanced and\/or Metastatic Solid Tumors","year":"2018"},{"key":"10.1016\/j.bioorg.2025.109417_bb0235","year":"2021"},{"key":"10.1016\/j.bioorg.2025.109417_bb0240","series-title":"Phase II Study of TSR-022 (Cobolimab) in Combination with TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma","year":"2018"},{"key":"10.1016\/j.bioorg.2025.109417_bb0245","series-title":"PHASE II NEOADJUVANT STUDY of PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION of TIM-3 INHIBITOR COBOLIMAB (TSR-022) and PD-1 INHIBITOR DOSTARLIMAB (TSR-042) in RESECTABLE STAGE III or OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)","year":"2019"},{"key":"10.1016\/j.bioorg.2025.109417_bb0250","year":"2017"},{"key":"10.1016\/j.bioorg.2025.109417_bb0255","series-title":"A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109417_bb0260","series-title":"Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Relapsed or Refractory Lymphoma","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0265","series-title":"A Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0270","series-title":"Phase I Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent\/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0275","series-title":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Recurrent\/Metastatic Nasopharyngeal Carcinoma","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0280","series-title":"A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection \u00b1Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer","year":"2023"},{"key":"10.1016\/j.bioorg.2025.109417_bb0285","series-title":"Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0290","year":"2023"},{"key":"10.1016\/j.bioorg.2025.109417_bb0295","series-title":"A Multicenter, Randomized, Open-Label Phase II\/III Clinical Study on the Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 Versus Investigator's Choice of Chemotherapy in Advanced Recurrent\/Metastatic Cervical Cancer","year":"2025"},{"key":"10.1016\/j.bioorg.2025.109417_bb0300","series-title":"A Phase Ib\/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","year":"2024"},{"key":"10.1016\/j.bioorg.2025.109417_bb0305","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109417_bb0310","series-title":"A Phase Ib\/II Study of BC3402, a Novel Anti-TIM3 Agent, in Combination With Tremelimumab Plus Durvalumab (STRIDE) in Advanced, Unresectable Hepatocellular Carcinoma","year":"2024"},{"key":"10.1016\/j.bioorg.2025.109417_bb0315","series-title":"A Phase Ib\/II Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma","year":"2023"},{"key":"10.1016\/j.bioorg.2025.109417_bb0320","series-title":"A Phase 1b Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of BC3402 in Combination With Azacitidine in Subjects With Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)","year":"2023"},{"key":"10.1016\/j.bioorg.2025.109417_bb0325","unstructured":"A Phase 1b\/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression. Institut de Recherches Internationales, S.; Regeneron, P., Eds. 2023."},{"key":"10.1016\/j.bioorg.2025.109417_bb0330","series-title":"Phase 1a\/1b, First-in-Human, Open Label, Dose Escalation and Dose Expansion Study of NB002, a Multifunctional TIM-3 Blocking Antibody, in Subjects With Advanced or Metastatic Solid Tumors","year":"2023"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109417_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101247","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia","volume":"34","author":"Daver","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.bioorg.2025.109417_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00609","article-title":"A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia","volume":"10","author":"Liao","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109417_bb0345","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2407-10-255","article-title":"The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.bioorg.2025.109417_bb0350","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109417_bb0355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1800991","article-title":"The next generation of immunotherapy for cancer: small molecules could make big waves","volume":"202","author":"Kerr","year":"2019","journal-title":"J. Immunol."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109417_bb0360","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1021\/acs.jmedchem.1c01336","article-title":"Fragment-based discovery of small molecules bound to T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3)","volume":"64","author":"Rietz","year":"2021","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109417_bb0365","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.1021\/acs.jmedchem.3c00960","article-title":"Discovery of small-molecule TIM-3 inhibitors for acute myeloid leukemia using pharmacophore-based virtual screening","volume":"66","author":"Abdel-Rahman","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109417_bb0370","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells","volume":"22","author":"Gon\u00e7alves Silva","year":"2017","journal-title":"eBioMedicine"},{"issue":"Suppl. 2","key":"10.1016\/j.bioorg.2025.109417_bb0375","doi-asserted-by":"crossref","first-page":"S1882","DOI":"10.4103\/jpbs.jpbs_402_25","article-title":"Molecular docking, molecular dynamics simulation, and pharmacophore-based virtual screening unveil natural compounds with TIM-3 inhibitory activity","volume":"17","author":"Alzain","year":"2025","journal-title":"J. Pharm. Bioallied Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109417_bb0380","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-023-02296-z","article-title":"C-5401331 identified as a novel T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) inhibitor to control acute myeloid leukemia (AML) cell proliferation","volume":"41","author":"Al Shahrani","year":"2024","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109417_bb0385","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109417_bb0390","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/gastro\/goz065","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy","volume":"8","author":"Rajha","year":"2020","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.bioorg.2025.109417_bb0395","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109417_bb0400","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.109417_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00268","article-title":"Current understanding of the mechanisms underlying immune evasion from PD-1\/PD-L1 immune checkpoint blockade in head and neck cancer","volume":"10","author":"Kok","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.109417_bb0410","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2021.03.049","article-title":"First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"151","author":"Mori","year":"2021","journal-title":"Eur. J. Cancer"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T13:49:31Z","timestamp":1768657771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":82,"alternative-id":["S0045206825012970"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109417","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent process in the development of TIM-3 antibodies and small-molecule inhibitors for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109417"}}